UNSPSC 51373204: Tapentadol hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C14H23NO.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71204KII53. European Medicines Agency schedules tapentadol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32145. The term tapentadol hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule tapentadol hydrochloride under HS 29222900 and SITC 51462.

As of Q4 2014, TAPENTADOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tapentadol hydrochloride bears US NLM identifiers UMLS ID C2718761 and NCI Concept Code C68922. SMILES: CC[C@@H](C1CCCC(C1)O)[C@@H](C)CN(C)C.CL.

UNSPSC 51373204 Tapentadol hydrochloride is a Commodity code that spans opioid pharmaceutical products procured by state and local health agencies, but recent state and local opportunities show little direct solicitation activity for this specific compound. The single most recent opportunity tagged to this code—Seminole County, Florida's IFB60459723LAS—actually solicits Naloxone and Safe Drug Deactivation Systems, products unrelated to tapentadol; the mismatch suggests possible tagging error in the source data. The other two opportunities in the recent-activity block—Texas Health and Human Services Commission's RFI on direct-to-manufacturer pharmacy programs and Minnesota's MMCAP cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—cover broad pharmaceutical procurement frameworks but do not reference tapentadol or opioid-specific compounds by name. State and local health departments, health and human services agencies, and cooperative purchasing alliances appear to be the primary issuing bodies when pharmaceutical commodities are solicited, though the volume and specificity of demand for tapentadol hydrochloride itself remain unclear from these records.

Geographic activity centers on Florida, Texas, and Minnesota based on recent solicitations, with broader multistate participation through cooperative vehicles like MMCAP that serve Oregon and other states. The Seminole County opportunity (due July 26, 2023, per the source posting) reflects county-level health procurement, while the Texas HHS and Minnesota MMCAP solicitations represent state-level and multistate cooperative activity. The Minnesota MMCAP RFP, due March 26, 2026, establishes multi-year contracts for generic pharmaceuticals across authorized wholesalers with pricing evaluation weighted 75 percent on competitiveness and 10 percent on fixed pricing, suggesting that state and local entities prioritize cost control in pharmaceutical procurement. Without direct recent solicitations naming tapentadol hydrochloride explicitly, the code shows minimal current pursuit signal for vendors focused on this specific opioid compound in state and local markets.